Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 737389, 5 pages
http://dx.doi.org/10.1155/2015/737389
Case Report

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV

Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA

Received 16 August 2015; Accepted 30 August 2015

Academic Editor: Raffaele Palmirotta

Copyright © 2015 Diwakar Davar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Perrin, J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke, “CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis,” The Journal of Immunology, vol. 157, no. 4, pp. 1333–1336, 1996. View at Google Scholar · View at Scopus
  3. F. Lühder, P. Höglund, J. P. Allison, C. Benoist, and D. Mathis, “Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes,” Journal of Experimental Medicine, vol. 187, no. 3, pp. 427–432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-B. Wang, F.-D. Shi, H. Li, B. J. Chambers, H. Link, and H.-G. Ljunggren, “Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis,” The Journal of Immunology, vol. 166, no. 10, pp. 6430–6436, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. X. F. Wang, Y. Lei, M. Chen, C. B. Chen, H. Ren, and T. D. Shi, “PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication,” Journal of Viral Hepatitis, vol. 20, no. 1, pp. 27–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti–PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2455–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. D. Wolchok, A. Hoos, S. O'Day et al., “Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria,” Clinical Cancer Research, vol. 15, no. 23, pp. 7412–7420, 2009. View at Publisher · View at Google Scholar · View at Scopus